LPAR1 and liver dysplastic nodule: Recently, LPAR1 and/or LPAR3 were proven to be upregulated in different DN mouse models, and treatment with a dual-LPAR1/3 antagonist ameliorated renal functions by regulating the LPA–GSK3β–SREBP1 axis [133].